-
Description
Entecavir Tablets 0.5 Mg - Oral Antiviral Medication
Entecavir tablets are a potent oral antiviral medication specifically designed to combat hepatitis B virus (HBV) infection. This pharmaceutical product is formulated to inhibit the replication of the virus within the human body, thereby reducing the viral load and preventing the progression of the disease.
Product Specifications:
- Active Ingredient: Entecavir monohydrate
- Strength: 0.5 mg per tablet
- Formulation: Oral tablet
- Recommended Dosage: As prescribed by a healthcare professional, typically once daily on an empty stomach
- Mechanism of Action: Entecavir is a nucleoside analogue that inhibits HBV DNA polymerase, effectively reducing viral replication
- Bioavailability: Rapidly absorbed with peak plasma concentrations reached within 0.5 to 1.5 hours
- Metabolism: Minimal hepatic metabolism
- Excretion: Primarily via the kidneys
Common Applications:
- Treatment of chronic hepatitis B virus infection in adults with evidence of active viral replication and either evidence of persistent elevations in aminotransferases (ALT or AST) or histologically active disease
- Use in patients with compensated liver disease and decompensated liver disease
User Groups:
- Adults diagnosed with chronic hepatitis B
- Individuals with liver disease related to HBV infection
Overview of Sandoz:
Sandoz, a division of the Novartis Group, is a global leader in the field of generic pharmaceuticals and biosimilars. With a history of over 130 years, Sandoz is renowned for its commitment to increasing access to high-quality medicines. The company's expertise in the development, manufacturing, and distribution of pharmaceuticals ensures that their products, including Entecavir tablets, meet the highest standards of safety and efficacy. Sandoz's dedication to innovation and quality makes them an authority in the antiviral medication space, providing healthcare solutions that address the needs of patients and healthcare providers worldwide.
